Evidence map›Paper›PMID 38727205›Full record

ArticleStatistics in medicine2024

Novel non-linear models for clinical trial analysis with longitudinal data: A tutorial using SAS for both frequentist and Bayesian methods.

Guoqiao Wang, Whedy Wang, Brian Mangal, Yijie Liao, Lon Schneider, Yan Li, Chengjie Xiong, Eric McDade, Richard Kennedy, Randall Bateman and 1 more

Abstract read
In one paragraph

Article in Statistics in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Letter to the Editor.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Guoqiao WangDepartment of Neurology, School of Medicine, Washington University, St. Louis, Missouri, USA.ORCID 0000-0002-6808-8737
Whedy WangTenaya Therapeutics, San Francisco, California, USA.
Brian MangalSolara Consulting Corp., North Vancouver, British Columbia, Canada.
Yijie LiaoNeogene Therapeutics, Inc., Santa Monica, California, USA.
Lon SchneiderDepartment of Psychiatry and The Behavioral Sciences, Department of Neurology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Yan LiDepartment of Neurology, School of Medicine, Washington University, St. Louis, Missouri, USA.
Chengjie XiongDivision of Biostatistics, School of Medicine, Washington University, St. Louis, Missouri, USA.
Eric McDadeDepartment of Neurology, School of Medicine, Washington University, St. Louis, Missouri, USA.
Richard KennedyDivision of Gerontology, Geriatrics, and Palliative Care, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Randall BatemanDepartment of Neurology, School of Medicine, Washington University, St. Louis, Missouri, USA.
Gary CutterDepartment of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Funding

DIAN-TU Primary Prevention Trial NfL Characterization Admin SuppU01AG059798 · NIA · WASHINGTON UNIVERSITY · PI MCDADE, ERIC MARTIN · 2018 to 2025
$97.9M
DIAN-TU Next Generation Prevention Trial - Data Request Management SupplementR01AG053267 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2017 to 2023
$34.9M
UAB Alzheimer's Disease Research CenterP30AG086401 · NIA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Erik D Roberson · 2024 to 2026
$17.1M
DIAN-TU Primary Prevention TrialR01AG059798 · NIA · WASHINGTON UNIVERSITY · PI Eric Martin McDade · 2026 to 2026
$2.2M
Innovative precision medicine methods in subgroup identification for Alzheimer's diseaseR21AG084054 · NIA · WASHINGTON UNIVERSITY · PI LIU, LEI, WANG, GUOQIAO · 2023 to 2024
$428k
NIA NIH HHS P30 AG086401NIA NIH HHS R01 AG053267NIA NIH HHS R01 AG059798NIA NIH HHS R21 AG084054NIA NIH HHS U01 AG059798NIH HHS 1R21AG08405401NIH HHS 1U01AG059798NIH HHS R01AG053267
6 · The paper itself

Abstract

Longitudinal data from clinical trials are commonly analyzed using mixed models for repeated measures (MMRM) when the time variable is categorical or linear mixed-effects models (ie, random effects model) when the time variable is continuous. In these models, statistical inference is typically based on the absolute difference in the adjusted mean change (for categorical time) or the rate of change (for continuous time). Previously, we proposed a novel approach: modeling the percentage reduction in disease progression associated with the treatment relative to the placebo decline using proportional models. This concept of proportionality provides an innovative and flexible method for simultaneously modeling different cohorts, multivariate endpoints, and jointly modeling continuous and survival endpoints. Through simulated data, we demonstrate the implementation of these models using SAS procedures in both frequentist and Bayesian approaches. Additionally, we introduce a novel method for implementing MMRM models (ie, analysis of response profile) using the nlmixed procedure.

Indexed as

Bayes TheoremClinical Trials as TopicComputer SimulationModels, StatisticalData Interpretation, StatisticalHumansLongitudinal StudiesNonlinear DynamicsProportional Hazards ModelsBayesian multivariate modelmixed models for repeated measuresmultivariate endpointproportional joint modelSAS

Identifiers

PMID38727205
PMCPMC11187662

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.